Engineered EVs with pathogen proteins: promising vaccine alternatives to LNP-mRNA vaccines

J Biomed Sci. 2024 Jan 17;31(1):9. doi: 10.1186/s12929-024-01000-1.

Abstract

Extracellular vesicles (EVs) are tiny, lipid membrane-bound structures that are released by most cells. They play a vital role in facilitating intercellular communication by delivering bioactive cargoes to recipient cells and triggering cellular as well as biological responses. EVs have enormous potential for therapeutic applications as native or engineered exosomes. Native EVs are naturally released by cells without undergoing any modifications to either the exosomes or the cells that secrete them. In contrast, engineered EVs have been deliberately modified post-secretion or through genetic engineering of the secreting cells to alter their composition. Here we propose that engineered EVs displaying pathogen proteins could serve as promising alternatives to lipid nanoparticle (LNP)-mRNA vaccines. By leveraging their unique characteristics, these engineered EVs have the potential to overcome certain limitations associated with LNP-mRNA vaccines.

Keywords: EV-based protein vaccines; Exosomes; Extracellular vesicles (EVs); LNP-mRNA vaccines; Mesenchymal stem/stromal cell (MSC).

Publication types

  • Review

MeSH terms

  • Exosomes* / genetics
  • Extracellular Vesicles* / metabolism
  • Mesenchymal Stem Cells* / metabolism
  • Vaccines* / genetics
  • mRNA Vaccines

Substances

  • mRNA Vaccines
  • Vaccines